Speech-Language Pathologists in Holmes, NY Accepting Medicare
3 Speech-Language Pathologists found. Showing 1 - 3
 Elisa A. Dazi, MS,CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 242 S White Rock Rd, Holmes, NY 12531 Phone: 845-878-7286 |
Gail Plaut, M.S., CCC-S/LP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 19 Burr Ln, Holmes, NY 12531 Phone: 914-589-9193 |
Mrs. Barbara Marie O'rourke, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 184 Milltown Rd, Holmes, NY 12531 Phone: 845-222-8589 |
News Archive
US may be losing ground as the leader in biomedical research
The United States may be losing ground as the leader in biomedical research and within the next five years will be second to China in the funds it spends for R&D, according to Francis Collins, M.D., Ph.D, director of the National Institutes of Health.
Biovest receives Rapporteur and Co-Rapporteur designation for BiovaxID personalized cancer vaccine
Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that the European Medicines Agency (EMA) has notified Biovest regarding the official designation of the Rapporteur and Co-Rapporteur for BiovaxID, a personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma.
Older adults no more distractible than younger adults
Despite previous research suggesting that older adults are more distractible, new research shows they are no more distractible than younger adults when asked to focus their attention on their sense of sight or sound, or when asked to switch their attention from one sense to the other.
Veterans who suffer from "Gulf War illness" have impaired function of mitochondria
Researchers at the UC San Diego School of Medicine have demonstrated for the first time that veterans of the 1990-91 Persian Gulf War who suffer from "Gulf War illness" have impaired function of mitochondria - the energy powerhouses of cells.
Taiho Pharmaceutical obtains approval in Japan for anticancer drug Lonsurf
Taiho Pharmaceutical Co., Ltd. (Tokyo, President: Masayuki Kobayashi) announced on March 24 that it has obtained approval in Japan from the Ministry of Health, Labour and Welfare to manufacture and market the oral combination anticancer drug "Lonsurf(R) combination tablet T15, T20" (nonproprietary names: trifluridine and tipiracil hydrochloride; development code: TAS-102), for the treatment of patients with unresectable advanced or recurrent colorectal cancer (only if refractory to standard therapies).
› Verified 8 days ago